|  |  |
| --- | --- |
| Title of the Project |  |
| Name of Researcher |  |
| Discipline/ Specify Specialty  (e.g., PhD, M.Phil., Research Project) |  |
| Supervisor / PI / Funding Agency |  |
| Institution |  |
| Study Design |  |
| Study Population |  |

Ref. No. GCUF/ERC/………… Dated:…………..

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Please answer each question (check ✓ appropriate box) | | YES | NO | N/A |
| 1 | Have you, before filling in this form, read a relevant research ethics guideline of animal, human or biological material research? |  |  |  |
| 2 | Is the project multidisciplinary with involvement of different departments / institutes? |  |  |  |
| 3 | Does the PI/Co-PIs of the project (early stage/experienced) have appropriate scientific skills and experience for execution of the project under consideration? |  |  |  |
| 4 | Does the study involve participants who are particularly vulnerable? (patients with sensitive medical conditions e.g., HIV/AIDS, drug addiction) or are unable to give informed consent (e.g., children, people with learning disabilities)? |  |  |  |
| 5 | Does the study involve archival material collected during research/routine laboratory testing and the material cannot be traced to its origin or cannot be accessed? |  |  |  |
| 6 | If the answer to the items 2, 4 and 5 is yes, then have you taken formal approval from the collaborating institutes/organizations/centers? |  |  |  |
| 7 | Is there any potential conflict of interest relating to the study? If yes, then have you declared the nature of conflict?(This declaration should be made a part of any existing proforma) |  |  |  |
| 8 | Will financial inducements (other than reasonable expenses and compensation for time) be offered to participants? |  |  |  |
| 9 | Will drugs, placebos, or other substances (e.g., food or drink constituents, dietary supplements) be administered to the study participants? |  |  |  |
| 10 | Does this study involve handling, transportation and storage of Infectious agents, toxins, or chemicals (pathogenic to humans, animals, or plants)? |  |  |  |
| 11 | If answer to 10 is yes, then are the standard biosafety measures (contamination control spill response, waste management, use of protective apparel, and inventory control) ensured for the execution of this project? |  |  |  |
| 12 | If the study involves distribution of questionnaires to the participants, has the right to Response Omission and Anonymity been provided to them? |  |  |  |
| 13 | In case of animal studies, have you considered alternatives (*in-vitro* systems, computer simulations and/or mathematical models) to reduce or replace the use of animals as far as possible? |  |  |  |
| 14 | Will you make sure that the health of humans/animals be given prior consideration and avoid or minimize discomfort, distress, and all procedures will be kept aseptic, painless and minimally intrusive? |  |  |  |
| 15 | Will you provide adequate care to all humans/animals and ailing study subjects shall be properly treated by the qualified care providers and will be removed from further study? |  |  |  |
| 16 | Will you ensure confidentiality and data protection related to study participants? |  |  |  |
| 17 | Will you share study findings with the participants and ERC if/ when asked? |  |  |  |
| 18 | Will you make sure that the results are only used for research purpose and information disseminated only through research publication / conference papers/presentations? |  |  |  |
| 19 | Have you obtained the prior consent with explicit right of the participants to include them or to withdraw from study at their will? |  |  |  |

***NOTE: Duly filled and signed Performa should be submitted to the ERC OFFICE, along with the following documents:***

I. Title Page of Research Synopsis/ Project and Summary

II. Consent from the collaborating institution, if applicable (attach the letter of approval)

A Copy of the filled Proforma may also be emailed (Microsoft Word) at following email addresses:

[muzammal63@yahoo.com](mailto:farjabeen2004@yahoo.co.in)

***Declaration: I/We declare that all the information given in this form and written in the proposal is correct and***

***I/We will abide by the ethical guidelines relevant to this research. I/We will reapply for ethical approval if there is a significant change or revision in the design or protocol of the proposed study.***

|  |  |  |  |
| --- | --- | --- | --- |
| **Researcher** | **Supervisor** | **Co-Supervisor(s)** | **Head of Department** |
| Signature:  Name:  Cell # | Signature  Name:  Designation:  Department:  Institution: | Signature:  Name:  Designation:  Department:  Institution: | Signature:  Name:  Department: |

For ERC Office use only:

|  |  |  |  |
| --- | --- | --- | --- |
| Approved | Not Approved | Deferred | More Information required |
|  |  |  |  |
| Comments: | | | |

**Prof. Dr. Muhammad Hidayat Rasool**

Secretary, ERC

Government College University Faisalabad, Pakistan.

Email: [drmhrasool@gcuf.edu.pk](mailto:drmhrasool@gcuf.edu.pk)

**Prof. Dr. Farhat Jabeen**

Chairperson, ERC

Government College University Faisalabad, Pakistan.

Email: [farjabeen@gcuf.edu.pk](mailto:farjabeen@gcuf.edu.pk)

Ref. No. GCUF/ERC/………… Dated:…………..

**CERTIFICATE OF APPROVAL**

Members of the Ethics Review Committee, Government College University Faisalabad have evaluated the research proposal entitled:

…………………………………………………………………………………………………

Submitted by:

…………………………………………………………………………………………………

The evaluation committee believes that the likelihood and degree of discomfort to humans/ animal subjects expected during this study are not greater than those usually faced in daily life or during the performance of routine physical examinations or tests. Furthermore, no genetically modified organism is being used in this study and during this study there will be neither any hazard to the environment nor any chance of COVID-19 dissemination.

The study has been approved for a period of …………………. years w.e.f. ……………………

The investigators will follow the tenets of declaration of Helsinki and Stockholm Convention. If any change is registered in the protocols of study or any extension in the period of the study, it should be notified to the Ethics Review Committee for approval.

**Prof. Dr. Muhammad Hidayat Rasool**

Secretary, ERC

Government College University Faisalabad, Pakistan.

Email: [drmhrasool@gcuf.edu.pk](mailto:drmhrasool@gcuf.edu.pk)

**Prof. Dr. Farhat Jabeen**

Chairperson, ERC

Government College University Faisalabad, Pakistan.

Email: [farjabeen2004@yahoo.co.in](mailto:farjabeen2004@yahoo.co.in)